Endothelin-1 (ET-1) exerts its biological actions through two receptor subtypes: ET A and ET B . We demonstrated previously that ET-1 induces systemic and renal cortical vasoconstriction via ET A , whereas ET B mediates medullary vasodilation. Congestive heart failure (CHF) is characterized by increased vascular resistance and impaired renal hemodynamic and excretory function. While the pathophysiological effects of ET-1 in CHF are well established, the status of ET A and ET B receptors in the kidney is poorly characterized. We studied the immunostaining and localization of ET A and ET B in the renal cortex and medulla of rats with experimental CHF induced by aorto-caval fistula. Rats with CHF were further subdivided, based on their daily urinary sodium excretion (UNaV), into rats with compensated (UNaVϾ1200 Eq/day) and decompensated CHF (UNaVϽ200 Eq/day). ET A is predominantly localized to the cortex, mainly in the peritubular capillaries, and is upregulated in both rats with compensated and decompensated CHF compared with sham operated controls. In contrast, ET B is preferentially expressed in the outer and inner medulla, mainly in vasa recta, thick ascending limb of Henle's loop and collecting duct (CD). While compensated CHF is associated with upregulation of ET B in the CD and vasa recta, decompensated CHF is accompanied with enhanced ET B abundance in the vasa recta and remarkable downregulation of this receptor subtype in the CD. The findings suggest that upregulation of ET A may lead to a decrease in cortical blood flow while upregulation of ET B in the vasa recta probably contributed to the preservation of medullary blood flow. Furthermore, downregulation of ET B in the CD, noted only in rats with decompensated CHF, could contribute to sodium retention in that subgroup.
P-95 LOSARTAN ON NITRIC OXIDE IN PATIENTS WITH HYPERTENSION
With the aim of evaluating the action of losartan on serum and urinary nitric oxide (NO) levels in patients with essential hypertension a group of thirty untreated hypertensive patients (age: 51.34 Ϯ 1.54 years, 15 males 15 females) were included. Determinations of NO (Griess Reagent) in serum and 24-hour urinary excretion were carried out on baseline and after 6 weeks of losartan 50 to 100 mg given once daily. All measurement carried out between 7am and 9am.
Results are shown as follows:
In conclusion, Losartan at a dosage of 50 to 100 mg/daily showed statistically significant clinical antihypertensive action accompanied with increment in serum and urinary NO levels. Renal NO clearance was not modified by treatment. Results indicate that losartan restoring nitric oxide production might improve endothelial function in patients with essential hypertension. Hyperhomocysteinemia comprises a well-established independent risk factor for cardiovascular atherosclerotic disease. Although it is a common feature in diabetic hypertensives, the incidence of hyperhomocysteinemia and its correlation with salt sensitivity has not been thoroughly investigated in non-diabetic, essential hypertensive patients (pts).
We studied 942 consecutive non-diabetic pts with uncomplicated essential hypertension, after a 2-week wash-out period. Pts with primary hyperhomocysteinemia were excluded. Plasma homocysteine was measured in the same day with 24-hour urine collection for determination of urine sodium concentration (NaC) and total urine sodium excretion (NaT).
When classified to quartiles according to plasma homocysteine values, a progressive significant increase mainly for NaC (114.0, 122.5, 126.6 and 141.4 mEq/L, Fϭ22.63, pϽ0.001), but also for NaT (199.7, 224.3, 215 .7and 233.0 mEq/24h, Fϭ3.96, pϭ0.02) was observed. It is noteworthy that pts of the uppermost quartile had a mean homocysteine value Ͼ15 mol/L, thus considered as suffering from mild hyperhomocysteinemia. Inversely, grouping of pts in NaC quartiles was accompanied by a significant increase in plasma homocysteine levels (11.36, 12.96, 12.40 and 14.57 mol/L, Fϭ13.65, pϽ0.00001) . Overall, homocysteine levels correlated with NaC (rϭ0.252, pϽ0.00001).
In conclusion, increased dietary salt ingestion as expressed by 24-h urine Na measurements, is associated with higher plasma homocysteine levels in non-diabetic hypertensives.
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P-97 GENE TRANSFER OF HUMAN GTP CYCLOHYDROLASE I RESTORES SUPEROXIDE-INDUCED ARTERIAL TETRAHYDROBIOPTERIN DEFICIENCY AND ENDOTHELIAL DYSFUNCTION IN DOCA-SALT HYPERTENSIVE RATS

